Clinical Trial

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Study acronym: EMPA[10-20]
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-12 -> 2028-05 2026-07-28
minor Completion pushed: 2027-12 -> 2028-05 2026-07-28
Trial Details
NCT Number NCT07074418
Lead Sponsor Centre Hospitalier Universitaire de Nice
Collaborators: Boehringer Ingelheim
Conditions Chronic Kidney Diseases
Enrollment 34 participants
Start Date 2026-09
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-27